Tyrosine kinase inhibitors and molecularly driven therapeutic approaches for canine lymphoma: a systematic review and meta-analysis
Frontiers in Veterinary Science · 12.08.2026 · 13
DOI: 10.3389/fvets.2026.1852091 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Veterinary Science, online erschienen am 12.08.2026. Verfasst von Yali Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Small Animal Medicine, College of Veterinary Medicine, China Agricultural University, Beijing, China. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Canine lymphoma (cL), the second most common canine cancer after mammary carcinoma, presents therapeutic challenges due to limitations of conventional regimens, necessitating novel therapeutic approaches. Tyrosine kinase inhibitors (TKIs), which have demonstrated efficacy in human non-Hodgkin lymphoma (NHL), are increasingly being investigated as targeted therapies for cL, which also serves as a valuable translational model for NHL research.
Objectives
To systematically evaluate the efficacy of TKIs in the treatment of cL.
Methods
A comprehensive search of PubMed, Web of Science, Cochrane, and Embase databases was conducted, encompassing studies published between January 1, 2004 and January 1, 2026, using controlled vocabulary terms including “Canine,” “Dogs,” “Lymphoma,” and “Tyrosine Kinase Inhibitors”. A meta-analysis was subsequently performed to evaluate the efficacy of TKIs.
Results
Seventeen articles were included, comprising 11 clinical trials and 9 in vitro experiments, with some studies encompassing both methodologies. A meta-analysis encompassing 101 dogs from 11 clinical trials showed an objective response rate (ORR) of 42% (95% CI: 32–53%; common-effect model), indicating moderate antitumor activity. Notably, canine T-cell lymphoma (ORR = 0.63) may exhibit a higher response rate compared to canine B-cell lymphoma (ORR = 0.27).
Conclusions
TKIs show moderate therapeutic activity in cL and support the role of dogs as a translational model for NHL research. However, further studies are needed to confirm their efficacy and safety and to explore optimal combination and personalized treatment strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Small Animal Medicine, College of Veterinary Medicine, China Agricultural University, Beijing, China.
- Department of Large Animal Medicine, College of Veterinary Medicine, China Agricultural University, Beijing, China.
- Department of Small Animal Medicine and Surgery, University of Veterinary Medicine Hannover, Hannover, Germany.
- Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Jilin University, Changchun, Jilin, China.
- Veterinary Teaching Hospital, China Agricultural University, Beijing, China.
- Institute of Medical Genetics, University Medical Center Rostock, Rostock, Germany.
Zitieren
APA
Chen, Y., Gao, Y., Li, S., Liu, B., Nolte, I., Murua Escobar, H., & Yu, F. (2026). Tyrosine kinase inhibitors and molecularly driven therapeutic approaches for canine lymphoma: a systematic review and meta-analysis. Frontiers in Veterinary Science, 13. https://doi.org/10.3389/fvets.2026.1852091
Vancouver
Chen Y, Gao Y, Li S, Liu B, Nolte I, Murua Escobar H, et al. Tyrosine kinase inhibitors and molecularly driven therapeutic approaches for canine lymphoma: a systematic review and meta-analysis. Frontiers in Veterinary Science. 2026;13. doi:10.3389/fvets.2026.1852091
BibTeX
@article{Chen2026,
author = {Chen, Yali and Gao, Yu and Li, Shumin and Liu, Bo and Nolte, Ingo and Murua Escobar, Hugo and Yu, Feng},
title = {Tyrosine kinase inhibitors and molecularly driven therapeutic approaches for canine lymphoma: a systematic review and meta-analysis},
journal = {Frontiers in Veterinary Science},
year = {2026},
volume = {13},
doi = {10.3389/fvets.2026.1852091}
}
EUVIMED